BioSpace News Archive

CorMedix Inc. (Nasdaq: CRMD) today announced that the United States Patent and Trademark Office (USPTO) allowed its patent claims directed to the composition of a catheter lock solution for preventing infection and also preventing reduced blood flow in central venous catheters.

NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the multi-source Nanox.ARC, including the Nanox.CLOUD, its accompanying cloud-based infrastructure.

Nusano, Inc. announced Gregory Moffitt, PhD, Director of Target Development at Nusano, will present an overview of the company’s breakthrough production platform to the European Cooperation in Science and Technology Astatine-211 Working Group on May 4, 2023.

Day One Biopharmaceuticals (Nasdaq: DAWN) today announced its first quarter 2023 financial results and highlighted recent corporate achievements.

The Heart Failure Society of America (HFSA) today released a new scientific statement on iron deficiency in heart failure (HF).

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced its participation in the annual Digestive Disease Week conference being held this year May 6-9 in Chicago, IL.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conference and invited investors to participate by webcast.

Systimmune, Inc. announced that it will present clinical data from its lead programs at the ASCO Annual Meeting 2023 in Chicago in June.

Maze Therapeutics announced the signing of an exclusive worldwide license agreement with Sanofi for Maze’s glycogen synthase 1 program, including clinical candidate MZE001, which is currently in development for the treatment of Pompe disease and other potential indications.

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:00 a.m. ET to discuss results for the first quarter 2023 and to provide a corporate update.